Navigation Links
Miriam researcher helps develop global hepatitis C recommendations for injection-drug users
Date:7/25/2013

(PROVIDENCE, R.I.) A Miriam Hospital researcher has joined forces with international colleagues to call for new strategies to better manage and improve assessment and treatment for hepatitis C (HCV) infection in individuals who inject drugs.

Lynn E. Taylor, M.D., an HIV specialist focusing on HIV and viral hepatitis coinfection at The Miriam Hospital, was the only American physician invited to join the expert international panel that issued these first-of-its-kind recommendations. They were published online yesterday by the journal Clinical Infectious Diseases, just ahead of World Hepatitis Day on July 28.

The recommendations are part of a supplement entitled "Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs: Moving the Agenda Forward," developed in collaboration with the International Network on Hepatitis Care in Substance Users.

"In well-resourced parts of the world, most hepatitis C exists among people who currently inject drugs and those who have injected drugs in the past. However, treatment access and uptake among this population remains low even though we increasingly have effective treatments for hepatitis C, which is a curable disease," said Taylor.

"Research supporting our recommendations the first international set ever released for treating hepatitis C in people who inject drugs demonstrates that treatment can be successful when barriers to care are addressed within a supportive environment," she added. "In fact, the burden of liver disease worldwide could be dramatically reduced by increasing treatment for hepatitis C infection among people who inject drugs, by preventing forward transmission."

An estimated five million people in the U.S. have chronic HCV infection, a liver disease that may result in long-term health problems, including liver scarring, liver failure and liver cancer. According to the Centers for Disease Control and Prevention, approximately 12,000 people die every year from HCV-related liver disease.

Until recently, HCV treatment guidelines excluded people who inject drugs, due to concerns about poor adherence, adverse events and re-infection. However, successful HCV treatment studies among this population have challenged this paradigm. The new international guidelines present evidence-based recommendations for treating HCV among individuals who inject drugs with appropriate evaluation and support.

Taylor is also lead author on a separate paper, appearing in the same supplement of Clinical Infectious Diseases, which focuses on the need for improved HCV care of another subset of the HCV-infected population: those who inject drugs and are also infected with HIV.

Chronic HCV infection has become a leading cause of non-AIDS related illness and death among individuals infected with HIV. Due to overlapping routes of transmission, dual infection is common: in the United States, 30 percent of HIV-infected people have chronic HCV, which is spread via contaminated blood, often through injection drug use. However, newer research suggests it may also be transmitted sexually among HIV-infected men who have sex with other men.

"HIV-infected individuals contending with injection drug use are the most likely to be affected by HCV, but the least likely to have access to treatment for HCV," said Taylor. "They should have equal and universal access to HIV/AIDS, HCV and addiction prevention, care and treatment."

She says essential but basic steps include improving prevention and screening for both infections and engaging co-infected individuals who inject drugs in HIV and HCV care early after diagnoses.

"The benefits of therapeutic advances in HCV will be limited for this group until barriers such as cost and access are overcome," she added. "Even with HCV cure rates approaching 100 percent with newer medications, effectiveness at population level will require expanding HCV therapy on large scale. These recommendations are an important step towards the goal of elimination of hepatitis C."

Taylor is also director of the HIV/Viral Hepatitis Program at The Miriam Hospital and an assistant professor of medicine at The Warren Alpert Medical School of Brown University.


'/>"/>

Contact: Jessica Collins Grimes
jgrimes2@lifespan.org
Lifespan
Source:Eurekalert

Related medicine news :

1. Miriam study reveals financial benefits of a plant-based, Mediterranean diet
2. Miriam researchers urge physicians to ask younger men about erectile dysfunction symptoms
3. Researchers find potential new target to treat malignant pleural mesothelioma
4. Air Conditioning Can Dehydrate Skin and Eyes Reports Water and Health Researcher Sharon Kleyne
5. Researchers target HER1 receptor for peptide cancer vaccine, therapeutic agents
6. University Researcher, International Assistance Dog Week Founder Announce Partnership to Increase Employment for People with Disabilities Partnered with Assistance Dogs
7. Researcher develops peer-led program to help individuals with HIV adhere to treatment plans
8. University of Hawaii Cancer Center researchers report
9. Mount Sinai researchers discover mechanism behind development of autoimmune hepatitis
10. Dead gene comes to life, puts chill on inflammation, Stanford researchers find
11. Researchers identify 146 contemporary medical practices offering no net benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Today, Jefferson Health in Philadelphia ... announced an agreement to create the Jane and Leonard Korman Respiratory Institute in ... Leonard Korman Family Foundation. The collaboration leverages the strengths of each organization and ...
(Date:4/27/2017)... ... ... Healthcare companies are trying to meet talent shortages and find new ways to ... “If you’re a healthcare executive open to new opportunities this year you’re probably taking ... you are for a new job search. I’ve heard from countless job seekers in ...
(Date:4/27/2017)... ... 27, 2017 , ... The American Brain Foundation last night ... Neurology Award (PLINA). The couple joins a prestigious list of past PLINA winners, ... actor Michael J. Fox and former U.S. Attorney General Janet Reno. , Smith ...
(Date:4/27/2017)... ... 2017 , ... SyncDog, Inc. , the leading ISV ... 2017 in Santa Clara, California. Each year, MobileIron Live! assembles mobility innovators, ... maximize the benefits of mobility in their operations securely. MobileIron is ...
(Date:4/27/2017)... Malibu, CA (PRWEB) , ... April 27, 2017 , ... ... United States with an oil many times purer and more potent than the market ... mountain air of Gstaad, Switzerland, as well as a patented chromatography process for extraction, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: